Advisers to the FDA will debate if the virus has mutated enough since last winter to require a tweak to the formula.

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials ...

Long before he joined the FDA to run the center that regulates vaccines, Vinay Prasad argued against COVID shots for kids. Among his many criticisms of the United States’ approach to combatting ...

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and ...

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

We have to admit to ourselves that America is deeply divided on the policy issue of repeat COVID-19 vaccine doses or boosters ...

The truth is that for most of that, for many Americans, we simply do not know the answer to whether or not they should be ...

The FDA's new vaccine guidelines focus on older adults, citing insufficient evidence for the need for additional COVID shots ...

The Trump administration's new COVID-19 vaccine plan limits access to high-risk groups, requiring further trials for low-risk individuals, marking a major policy shift amid scientific uncertainty and ...

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it. The agreement – which ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...